Zobrazeno 1 - 10
of 340
pro vyhledávání: '"35"'
Autor:
David Malka, Cedric Lecaille, Anne-Laure Bignon, Nicolas Williet, Caroline Pétorin, Thomas Aparicio, Jérôme Desramé, Jean-Marc Phelip, Côme Lepage, Eric Francois, Yves Rinaldi, Anthony Turpin, Prodige Investigators, Karine Le Malicot, Laetitia Dahan, Jean-François Seitz, Christine Rebischung, Olivier Bouché, Jean-Baptiste Bachet
Publikováno v:
Journal of Clinical Oncology. 39:3242-3250
PURPOSE Metastatic pancreatic cancer (mPC) still harbors a dismal prognosis. Our previous trial (PRODIGE 4—ACCORD 11) demonstrated the superiority of 6-month chemotherapy with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) over
Publikováno v:
Scopus-Elsevier
PURPOSE This prospective phase II study was designed to test the activity and toxicity of a regimen of fluorouracil (5-FU) and cisplatin (CDDP) in combination with radiation therapy in the treatment of epidermoid cancer of the anal canal. PATIENTS AN
Autor:
Erin Jensen, M. Catherine Pietanza, Andrew G. Robinson, Martin Reck, Rina Hui, Julie R. Brahmer, Nir Peled, Ticiana A. Leal, Jonathan W. Riess, Andrea Fülöp, Mary O'Brien, Delvys Rodriguez-Abreu, Katsuyuki Hotta, Ali Tafreshi, Bin Zhao, Suman Rao, Tibor Csőszi, Maya Gottfried, Sinead Cuffe
Publikováno v:
Journal of Clinical Oncology. 39:2339-2349
PURPOSE We report the first 5-year follow-up of any first-line phase III immunotherapy trial for non–small-cell lung cancer (NSCLC). KEYNOTE-024 (ClinicalTrials.gov identifier: NCT02142738 ) is an open-label, randomized controlled trial of pembroli
Autor:
Sharon M. Castellino, Paul C. Nathan, Raymond J. Hutchinson, Wendy M. Leisenring, Kayla Stratton, Gregory T. Armstrong, Suzanne L. Wolden, Kevin C. Oeffinger, Susan A. Smith, Melissa M. Hudson, Dana Barnea, Charles A. Sklar, Leslie L. Robison, Louis S. Constine, Lisa Diller, Rebecca M. Howell, Tara O. Henderson
Publikováno v:
J Clin Oncol
PURPOSE To determine the incidence of serious chronic health conditions among survivors of pediatric Hodgkin lymphoma (HL), compare by era of therapy and by selected cancer therapies, and provide estimates of risks associated with contemporary therap
Autor:
Daniel A. Mulrooney, Qi Liu, Paul C. Nathan, Melissa M. Hudson, Zachary J. Ward, Eric J. Chow, Yutaka Yasui, Gregory T. Armstrong, Kevin C. Oeffinger, William L. Border, Matthew J. Ehrhardt, Saro H. Armenian, Aeysha Chaudhry, Jennifer M. Yeh, Todd M. Gibson, Lisa Diller, Leslie L. Robison, Anju Nohria, Louis S. Constine, Wendy M. Leisenring, Joy M. Fulbright, Rebecca M. Howell
Publikováno v:
J Clin Oncol
PURPOSE Survivors of childhood cancer treated with anthracyclines and/or chest-directed radiation are at increased risk for heart failure (HF). The International Late Effects of Childhood Cancer Guideline Harmonization Group (IGHG) recommends risk-ba
Autor:
Polina Kaplan, Javier de la Serna, Malgorzata Wach, Sean Dolan, Phillip L. Campbell, Jae Hoon Lee, Martin Simkovic, Árpád Illés, Iryna Kraychok, Eric J. Avery, Wojciech Jurczak, Andrzej Pluta, Abraham Jacob, Tomas Kozak, Gerardo Musuraca, Daniel Lysák, Wei Liang, Priti Patel, Cheng Quah, Paolo Ghia
Publikováno v:
Journal of Clinical Oncology. 38:2849-2861
PURPOSE Acalabrutinib, a highly selective, potent, Bruton tyrosine kinase inhibitor, was evaluated in this global, multicenter, randomized, open-label, phase III study in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). MET
Autor:
Peter Kamper, Alexander Lindholm d'Amore, David W. Scott, Joseph M. Connors, Randy D. Gascoyne, Marcel Nijland, Sohrab P. Shah, Christian Steidl, Anja Mottok, Anke van den Berg, Stephen Hamilton-Dutoit, Fong Chun Chan, Alina S. Gerrie, Kerry J. Savage, Maryse M. Power, Arjan Diepstra, Francesco d'Amore
Publikováno v:
Chan, F C, Mottok, A, Gerrie, A S, Power, M, Nijland, M, Diepstra, A, van den Berg, A, Kamper, P, d'Amore, F, d'Amore, A L, Hamilton-Dutoit, S, Savage, K J, Shah, S P, Connors, J M, Gascoyne, R D, Scott, D W & Steidl, C 2017, ' Prognostic Model to Predict Post-Autologous Stem-Cell Transplantation Outcomes in Classical Hodgkin Lymphoma ', Journal of Clinical Oncology, vol. 35, no. 32, pp. 3722-3733 . https://doi.org/10.1200/JCO.2017.72.7925
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 35(32), 3722-3733. AMER SOC CLINICAL ONCOLOGY
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 35(32), 3722-3733. AMER SOC CLINICAL ONCOLOGY
Purpose Our aim was to capture the biology of classical Hodgkin lymphoma (cHL) at the time of relapse and discover novel and robust biomarkers that predict outcomes after autologous stem-cell transplantation (ASCT). Materials and Methods We performed
Autor:
Philip R. Debruyne, Maes A, Otto S. Hoekstra, Olivier Lenssen, M. Martens, Carl Van Laer, Isabel Hutsebaut, Remco de Bree, Nils Helsen, Laurens Carp, Eclyps investigators, Sabine Meersschout, Joost van Dinther, Danielle Van den Weyngaert, Tim Van den Wyngaert, Jan B. Vermorken, Sara Hakim, Sigrid Stroobants
Publikováno v:
Journal of Clinical Oncology, 35(30), 3458. American Society of Clinical Oncology
Journal of Clinical Oncology, 35(30), 3458-3464. American Society of Clinical Oncology
Journal of clinical oncology
Van Den Wyngaert, T, Helsen, N, Carp, L, Hakim, S, Martens, M J, Hutsebaut, I, Debruyne, P R, Maes, A L M, Van Dinther, J, Van Laer, C G, Hoekstra, O S, De Bree, R, Meersschout, S A E, Lenssen, O, Vermorken, J B, Van Den Weyngaert, D, Stroobants, S & ECLYPS investigators 2017, ' Fluorodeoxyglucose-positron emission tomography/computed tomography after concurrent chemoradiotherapy in locally advanced head-and-neck squamous cell cancer : The ECLYPS study ', Journal of Clinical Oncology, vol. 35, no. 30, pp. 3458-3464 . https://doi.org/10.1200/JCO.2017.73.5845
Journal of Clinical Oncology, 35(30), 3458-3464. American Society of Clinical Oncology
Journal of clinical oncology
Van Den Wyngaert, T, Helsen, N, Carp, L, Hakim, S, Martens, M J, Hutsebaut, I, Debruyne, P R, Maes, A L M, Van Dinther, J, Van Laer, C G, Hoekstra, O S, De Bree, R, Meersschout, S A E, Lenssen, O, Vermorken, J B, Van Den Weyngaert, D, Stroobants, S & ECLYPS investigators 2017, ' Fluorodeoxyglucose-positron emission tomography/computed tomography after concurrent chemoradiotherapy in locally advanced head-and-neck squamous cell cancer : The ECLYPS study ', Journal of Clinical Oncology, vol. 35, no. 30, pp. 3458-3464 . https://doi.org/10.1200/JCO.2017.73.5845
Purpose To assess the standardized implementation and reporting of surveillance [18F]fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) scan of the neck in locoregionally advanced head-and-neck squamous cell carcinoma (L
Autor:
Gerald H. Clamon, Mark A. Socinski, Neal Ready, Ying Zhang, Everett E. Vokes, Walter J. Curran, Benjamin Movsas, Xiaofei Wang, Steven E. Schild, Jeffrey D. Bradley, Joan H. Schiller, George R. Blumenschein, Thomas E. Stinchcombe, Herbert Pang, Harvey J. Cohen, Ramaswamy Govindan, Wallace Akerley, Karen Kelly
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 35, iss 25
Stinchcombe, TE; Zhang, Y; Vokes, EE; Schiller, JH; Bradley, JD; Kelly, K; et al.(2017). Pooled analysis of individual patient data on concurrent chemoradiotherapy for stage III non-small-cell lung cancer in elderly patients compared with younger patients who participated in US national cancer institute cooperative group studies. Journal of Clinical Oncology, 35(25), 2885-2892. doi: 10.1200/JCO.2016.71.4758. UC Davis: Retrieved from: http://www.escholarship.org/uc/item/0j4582gf
Stinchcombe, TE; Zhang, Y; Vokes, EE; Schiller, JH; Bradley, JD; Kelly, K; et al.(2017). Pooled analysis of individual patient data on concurrent chemoradiotherapy for stage III non-small-cell lung cancer in elderly patients compared with younger patients who participated in US national cancer institute cooperative group studies. Journal of Clinical Oncology, 35(25), 2885-2892. doi: 10.1200/JCO.2016.71.4758. UC Davis: Retrieved from: http://www.escholarship.org/uc/item/0j4582gf
Purpose Concurrent chemoradiotherapy is standard treatment for patients with stage III non–small-cell lung cancer. Elderly patients may experience increased rates of adverse events (AEs) or less benefit from concurrent chemoradiotherapy. Patients a
Autor:
Søren Cold, Marianne Ewertz, Hanne Melgaard Nielsen, Julia Kenholm, Dorte Carlsen, Malgorzata K Tuxen, Ann Knoop, Eva Balslev, Troels Bechmann, Erik Jakobsen, Hella Danø, Michael Andersson, Dorte Nielsen, Inger Højris, Henning T. Mouridsen, Bent Ejlertsen, Else Maae, Peter Michael Vestlev, Maj-Britt Jensen
Publikováno v:
Ejlertsen, B, Tuxen, M K, Jakobsen, E H, Jensen, M-B, Knoop, A S, Højris, I, Ewertz, M, Balslev, E, Danø, H, Vestlev, P M, Kenholm, J, Nielsen, D L, Bechmann, T, Andersson, M, Cold, S, Nielsen, H M, Maae, E, Carlsen, D & Mouridsen, H T 2017, ' Adjuvant Cyclophosphamide and Docetaxel With or Without Epirubicin for Early TOP2A-Normal Breast Cancer: DBCG 07-READ, an Open-Label, Phase III, Randomized Trial ', Journal of Clinical Oncology, vol. 35, no. 23, pp. 2639-2646 . https://doi.org/10.1200/JCO.2017.72.3494
Ejlertsen, B, Tuxen, M K, Jakobsen, E H, Jensen, M-B, Knoop, A S, Højris, I, Ewertz, M, Balslev, E, Danø, H, Vestlev, P M, Kenholm, J, Nielsen, D L, Bechmann, T, Andersson, M, Cold, S, Nielsen, H M, Maae, E, Carlsen, D & Mouridsen, H T 2017, ' Adjuvant Cyclophosphamide and Docetaxel With or Without Epirubicin for Early TOP2A-Normal Breast Cancer : DBCG 07-READ, an Open-Label, Phase III, Randomized Trial ', Journal of Clinical Oncology, vol. 35, no. 23, pp. 2639-2646 . https://doi.org/10.1200/JCO.2017.72.3494
Ejlertsen, B, Tuxen, M K, Jakobsen, E H, Jensen, M-B, Knoop, A S, Højris, I, Ewertz, M, Balslev, E, Danø, H, Vestlev, P M, Kenholm, J, Nielsen, D L, Bechmann, T, Andersson, M, Cold, S, Nielsen, H M, Maae, E, Carlsen, D & Mouridsen, H T 2017, ' Adjuvant Cyclophosphamide and Docetaxel With or Without Epirubicin for Early TOP2A-Normal Breast Cancer : DBCG 07-READ, an Open-Label, Phase III, Randomized Trial ', Journal of Clinical Oncology, vol. 35, no. 23, pp. 2639-2646 . https://doi.org/10.1200/JCO.2017.72.3494
Purpose Administration of anthracycline and taxane therapy in the adjuvant setting is considered a standard for breast cancer. We evaluated a non-anthracycline-based regimen in TOP2A-normal patients. Patients and Methods In this multicenter, open-lab